Intra-Cellular Therapies Inc.(ITCI)

Description: Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS). Its lead product candidate includes ITI-007, which is in various clinical trials for the treatment of exacerbated and residual schizophrenia; bipolar disorders; sleep deficits associated with neurologic and psychiatric disorders; behavioral disturbances associated with dementia, including Alzheimer's disease; sleep maintenance insomnia; major depressive disorders; and autism spectrum disorders, PTSD, and IED. The company also develops ITI-002 phosphodiesterase (PDE) 1 inhibitors, including ITI-214 program that is in Phase-I clinical trial for the treatment of cognitive dysfunction in schizophrenia, as well as in pre-clinical stage for the treatment of Parkinson's disease, cognitive impairment in Alzheimer's disease, and attention deficit/hyperactivity disorders; and ITI-002 internal program that is pre-clinical stage for cardiovascular and other diseases. In addition, it develops early stage drug development programs comprising ITI-012 casein kinase 1 inhibitors and ITI-009 gamma secretase activating protein inhibitors for Alzheimer's disease. Further, the company develops PDE2 and PDE9 targets for treating neurodegeneration and bioenergetic failure in various CNS diseases. It has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize the company's proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. The company is headquartered in New York, New York.

---

Keywords: Medicine Biopharmaceutical Alzheimer's Disease Neuroscience Parkinson's Disease Disorders Drug Development Mental Health Psychiatric Diagnosis Schizophrenia Psychiatry Dementia Dysfunction Treatment Of Parkinson's Disease Major Depressive Disorder Human Diseases Neurodegeneration Aging Associated Diseases Takeda Pharmaceutical Company Depressive Disorder Cognitive Disorders Insomnia Autism Autism Spectrum Disorder Bipolar Disorder Psychiatric Disorders Hyperactivity Disorder Learning Disabilities Ptsd Cognitive Impairment Cognitive Dysfunction Treatment Of Human Diseases Phosphodiesterase Cardiovascular And Other Diseases Cns Diseases Pde9

---

Home Page: www.intracellulartherapies.com

ITCI Technical Analysis

430 East 29th Street
New York, NY 10016
United States
Phone: 646 440 9333

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)